Market closedNon-fractional
BioMarin/BMRN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About BioMarin
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
Ticker
BMRN
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
San Rafael, United States
Employees
3,401
Website
www.biomarin.com
BioMarin Metrics
BasicAdvanced
$16B
Market cap
79.99
P/E ratio
$1.07
EPS
0.31
Beta
-
Dividend rate
Price and volume
Market cap
$16B
Beta
0.31
Financial strength
Current ratio
2.744
Quick ratio
1.548
Long term debt to equity
11.699
Total debt to equity
21.612
Interest coverage (TTM)
10.95%
Management effectiveness
Return on assets (TTM)
1.77%
Return on equity (TTM)
4.22%
Valuation
Price to earnings (TTM)
79.986
Price to revenue (TTM)
6.523
Price to book
3.2
Price to tangible book (TTM)
3.53
Price to free cash flow (TTM)
93.086
Growth
Revenue change (TTM)
13.74%
Earnings per share change (TTM)
188.87%
3-year revenue growth (CAGR)
10.25%
3-year earnings per share growth (CAGR)
-36.59%
What the Analysts think about BioMarin
Analyst Ratings
Majority rating from 28 analysts.
BioMarin Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$649M
0.40%
Net income
$89M
336.45%
Profit margin
13.65%
334.71%
BioMarin Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.29
$0.21
$0.11
$0.46
-
Expected
$0.23
$0.23
$0.23
$0.35
$0.34
Surprise
24.53%
-10.29%
-52.91%
33.33%
-
BioMarin News
AllArticlesVideos
U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease
PRNewsWire·2 days ago
BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET
PRNewsWire·4 days ago
BioMarin to Present Data Highlighting Significant Impact of VOXZOGO® (vosoritide) in Bone Health and Health-Related Quality of Life in Achondroplasia at 2024 International Conference on Children's Bone Health
PRNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BioMarin stock?
BioMarin (BMRN) has a market cap of $16B as of July 27, 2024.
What is the P/E ratio for BioMarin stock?
The price to earnings (P/E) ratio for BioMarin (BMRN) stock is 79.99 as of July 27, 2024.
Does BioMarin stock pay dividends?
No, BioMarin (BMRN) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next BioMarin dividend payment date?
BioMarin (BMRN) stock does not pay dividends to its shareholders.
What is the beta indicator for BioMarin?
BioMarin (BMRN) has a beta rating of 0.31. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell BioMarin stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.